Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Heart Biopsy May Help Diagnose EGPA in ANCA-negative Cases

A biopsy of heart muscle may aid in the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac involvement in patients negative for antineutrophil cytoplasmic antibodies (ANCAs) and with a negative skin biopsy, a case study suggests. The study, “Endomyocardial biopsy facilitates diagnosis of…

Procedure That Blocks Some Neck Nerves May Help Control EGPA

Stellate ganglion block, a procedure where a pain-relieving medicine is injected into the neck to block certain nerves, might be a successful therapeutic approach for eosinophilic granulomatosis with polyangiitis (EGPA), a recent case study suggests. The procedure helped control symptoms and lower corticosteroid doses, which are associated with detrimental…

PR3-ANCA Antibodies Tied to More Relapses in EGPA Patients

People with eosinophilic granulomatosis with polyangiitis (EGPA) who carry antibodies against the proteinase 3 (PR3) protein have more frequent relapses and a shorter time to relapse or death than patients without such antibodies, a South Korean study shows. These findings highlight the need to look for the presence of…

Kidney Specialists May Benefit Some EGPA Patients, Report Suggests

Kidney disease is less common among people with eosinophilic granulomatosis with polyangiitis (EGPA), but some patients may experience severe kidney damage and require management by specialists, a case report shows. The study, “Renal Involvement in Eosinophilic Granulomatosis With Polyangiitis,” was published in the journal Kidney International Reports.

Thyroid Med for Graves’ Disease Triggered AAV

A woman of childbearing years developed ANCA-associated vasculitis (AAV) after taking the thyroid medication methimazole to treat her Graves’ disease, a case report shows. The patient experienced signs of respiratory and kidney failure secondary to AAV, but her symptoms improved after discontinuing the medication and starting immunosuppressive medications. Four…

PANTHERx, Rare Disease Pharmacy, to Distribute Tavneos in US

Tavneos (avacopan), a recently approved add-on oral therapy for severe, active ANCA-associated vasculitis (AAV), will be distributed in the U.S. by PANTHERx, the country’s leading rare disease pharmacy. The announcement follows an agreement with ChemoCentryx, Tavneos’ developer, which selected the pharmacy as a limited distribution partner. “PANTHERx is proud…

FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA

The U.S. Food and Drug Administration (FDA) has approved Tavneos (avacopan) as an add-on therapy for people with severe active microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), the two most common forms of ANCA-associated vasculitis. The approval comes after an advisory committee narrowly supported avacopan’s approval…